2014/12/19 SCIENCE雜誌第346期 2015年科學關注焦點

Combination therapies that help harness T cells and other immune cells in the cancer fight are a key area to watch.

圖說：結合T細胞和其他免疫細胞的免疫療法，是與癌症戰鬥中值得被關注的關鍵領域。

PHOTOS: (LEFT) c DAVID SCHARF/SCIENCE SOURCE; (OPPOSITE) JOHN MOORE/GETTY IMAGES

COMBINED IMMUNOTHERAPY

結合免疫療法

Cancer immunotherapy, Science’s Breakthrough of 2013, continues to surge as clinical researchers amass evidence that the immune system can be a powerful ally against tumors.

癌症腫瘤免疫治療，自2013年起在科學界有重大的突破。不斷飆升的臨床研究積累數據證明，免疫系統是對抗癌症腫瘤的強大盟友。

One big focus now is mixing and matching treatments:combining two novel immunotherapies, for example, or an immune strategy with a targeted drug, radiation, or chemotherapy.

其中最大的矚目焦點是混搭──結合兩種新穎的免疫療法。例如：使用標靶藥物或輻射或化學治療等搭配免疫療法的治療策略。

Dozens of clinical trials are under way—ranging from a phase I study in melanoma that combines the recently approved immunotherapy drug ipilimumab with another treatment that slows blood vessel growth, to a phase III trial testing whether ipilimumab and chemotherapy outperform chemotherapy alone in treating lung cancer.

The results could make it easier for oncologists to match treatments to patients. But potential toxicity of the new strategies remains a concern.

內文摘錄自2014/12/19 SCIENCE雜誌第346期

SCIENCE雜誌網站內容請見：http://ppt.cc/33S4